Literature DB >> 1472461

Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors.

N Kadohama1, C Yarborough, D Zhou, S Chen, Y Osawa.   

Abstract

Mutant forms of aromatase cytochrome P-450 bearing modifications of amino acid residues Pro308 and Asp309 and expressed in transfected Chinese hamster ovary cells were subjected to kinetic analysis and inhibition studies. The Km for androstenedione for expressed wild type (11.0 +/- 0.3 nM SEM, n = 3) increased 4-, 25- and 31-fold for mutants Pro308Phe, Asp309Asn and Asp309Ala, respectively. There were significant differences in sensitivity among wild type and mutants to highly selective inhibitors of estrogen biosynthesis. 4-Hydroxyandrostenedione (4-OHA) a strong inhibitor of wild type aromatase activity (IC50 = 21 nM and Ki = 10 nM), was even more effective against mutant Pro308Phe (IC50 = 13 nM and Ki = 2.8 nM), but inhibition of mutants Asp309Asn and Asp309Ala was considerably less (IC50 = 345 and 330 nM and Ki = 55 and 79 nM, respectively). Expressed wild type aromatase and Pro308Phe aromatase were strongly inhibited by CGS 16949A (IC50 = 4.0 and 4.6 nM, respectively) whereas mutants Asp309Asn and Asp309Ala were markedly less sensitive (IC50 = 140 and 150 nM, respectively). CGS 18320B produced similar inhibition. Kinetic analyses produced Ki = 0.4 nM for CGS 16949A inhibition of wild type versus 1.1, 37 and 58 nM, respectively, against Pro308Phe, Asp309Asn and Asp309Ala. The results demonstrate significant changes in function resulting from single amino acid modifications of the aromatase enzyme. Our data indicate that mutation in Asp309 creates a major distortion in the substrate binding site, rendering the enzyme much less efficient for androstenedione aromatization. The substitution of Pro308 with Phe produces weaker affinity for androstenedione in the substrate pocket, but this alteration favors 4-OHA binding. Similarly, mutant Pro308Phe exhibits a slightly greater sensitivity to inhibition by CGS 18320B than does the wild type. These results indicate that residues Pro308 and Asp309 play critical roles in determining substrate specificity and catalytic capability in aromatase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472461     DOI: 10.1016/0960-0760(92)90295-t

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Binding features of steroidal and nonsteroidal inhibitors.

Authors:  Yanyan Hong; Rumana Rashid; Shiuan Chen
Journal:  Steroids       Date:  2011-03-21       Impact factor: 2.668

2.  Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer.

Authors:  J Narashima Murthy; M Nagaraju; G Madhavi Sastry; A Raghuram Rao; G Narahari Sastry
Journal:  J Comput Aided Mol Des       Date:  2006-04-22       Impact factor: 3.686

3.  Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors.

Authors:  T I Oprea; A E García
Journal:  J Comput Aided Mol Des       Date:  1996-06       Impact factor: 3.686

Review 4.  Aromatase inhibitors--mechanisms for non-steroidal inhibitors.

Authors:  H V Vanden Bossche; H Moereels; L M Koymans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Structural basis for androgen specificity and oestrogen synthesis in human aromatase.

Authors:  Debashis Ghosh; Jennifer Griswold; Mary Erman; Walter Pangborn
Journal:  Nature       Date:  2009-01-08       Impact factor: 49.962

6.  Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study.

Authors:  Y C Kao; C Zhou; M Sherman; C A Laughton; S Chen
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

7.  Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.

Authors:  W R Miller; M Stuart; T Sahmoud; J M Dixon
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.